Wilson Therapeutics appoints Carl Bjartmar as chief medical officer
Privately-held Swedish biopharma company Wilson Therapeutics has appointed Carl Bjartmar as chief medical officer.
Dr Bjartmar will report to Jonas Hansson, chief executive officer, and will join the company's management team. He brings 13 years of experience in pharma and joins from Genzyme, a Sanofi company (Euronext: SAN), where he had roles leading clinical development of treatments for rare and neurological disorders.
Jonas Hansson, chief executive officer of Wilson Therapeutics, said: "We are pleased to welcome Carl to Wilson Therapeutics. We believe that Carl's extensive expertise within the development of novel therapies for rare diseases will be a tremendous asset to the company to help us reach our goal of developing new treatments for this serious and devastating disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze